By Ben James ( December 19, 2012, 7:50 PM EST) -- GlaxoSmithKline agreed to pay $150 million to end a direct purchaser antitrust class action accusing GSK of filing sham petitions with the U.S. Food and Drug Administration to delay generic alternatives to Flonase nasal spray, Meijer Inc. told a Pennsylvania federal court last week....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.